Showing results (171-180 of 3,148) with videos related to
Sort By:
Pageof 315
Neuro-Oncology|March 25, 2017
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) studyAnuradha Banerjee, Regina I Jakacki, Arzu Onar-Thomas, et al.Neuro-Oncology|March 25, 2017
Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumorYoung Eun Lee, Seung Ah Choi, Pil Ae Kwack, et al.Neuro-Oncology|April 6, 2017
Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomasKirsi J Granberg, Matti Annala, Birgitta Lehtinen, et al.Neuro-Oncology|April 6, 2017
The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survivalEric M Thompson, Stephen T Keir, Talaignair Venkatraman, et al.Neuro-Oncology|April 6, 2017
Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issuesArjun Sahgal, Mark Ruschin, Lijun Ma, et al.Neuro-Oncology|April 10, 2017
Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)Riccardo Soffietti, Ufuk Abacioglu, Brigitta Baumert, et al.Neuro-Oncology|March 28, 2014
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade gliomaSeunggu J Han, John D Rolston, Annette M Molinaro, et al.Neuro-Oncology|April 12, 2014
Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterationsDominique Figarella-Branger, Karima Mokhtari, Caroline Dehais, et al.Neuro-Oncology|March 7, 2014
Accuracy of distinguishing between dysembryoplastic neuroepithelial tumors and other epileptogenic brain neoplasms with [¹¹C]methionine PETSylvain Rheims, Sebastià Rubi, Sandrine Bouvard, et al.Neuro-Oncology|January 1, 2017
Impaired health-related quality of life in meningioma patients-a systematic reviewAmir H Zamanipoor Najafabadi, Marthe C M Peeters, Linda Dirven, et al.Pageof 315